TY - JOUR
T1 - Discovery of mixed type thymidine phosphorylase inhibitors endowed with antiangiogenic properties
T2 - synthesis, pharmacological evaluation and molecular docking study of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones. Part II
AU - Bera, Hriday
AU - Ojha, Probir Kumar
AU - Tan, Bee Jen
AU - Sun, Lingyi
AU - Dolzhenko, Anton V
AU - Chui, Wai-Keung
AU - Chiu, Gigi Nagar Chee
PY - 2014
Y1 - 2014
N2 - In our drug discovery program, a series of 2-thioxo-pyrazolo[1,5-a][1,3,5] triazin-4-ones were designed, synthesized and evaluated for their TP inhibitory potential. All the synthesized analogues conferred a varying degree of TP inhibitory activity, comparable or better than positive control, 7-deazaxanthine (7-DX, 2) (IC50 value = 42.63 ?M). A systematic approach to the lead optimization identified compounds 3c and 4a as the most promising TP inhibitors, exhibiting mixed mode of enzyme inhibition. Moreover, selected compounds demonstrated the ability to attenuate the expression of the angiogenic markers (viz. MMP-9 and VEGF) in MDA-MB-231 cells at sublethal concentrations. In addition, molecular docking studies revealed the plausible binding orientation of these inhibitors towards TP, which was in accordance with the experimental results. Taken as a whole, these compounds would constitute a new direction for the design of novel TP inhibitors with promising antiangiogenic properties. ? 2014 Elsevier Masson SAS. All rights reserved.
AB - In our drug discovery program, a series of 2-thioxo-pyrazolo[1,5-a][1,3,5] triazin-4-ones were designed, synthesized and evaluated for their TP inhibitory potential. All the synthesized analogues conferred a varying degree of TP inhibitory activity, comparable or better than positive control, 7-deazaxanthine (7-DX, 2) (IC50 value = 42.63 ?M). A systematic approach to the lead optimization identified compounds 3c and 4a as the most promising TP inhibitors, exhibiting mixed mode of enzyme inhibition. Moreover, selected compounds demonstrated the ability to attenuate the expression of the angiogenic markers (viz. MMP-9 and VEGF) in MDA-MB-231 cells at sublethal concentrations. In addition, molecular docking studies revealed the plausible binding orientation of these inhibitors towards TP, which was in accordance with the experimental results. Taken as a whole, these compounds would constitute a new direction for the design of novel TP inhibitors with promising antiangiogenic properties. ? 2014 Elsevier Masson SAS. All rights reserved.
UR - http://www.sciencedirect.com/science/article/pii/S0223523414002773
U2 - 10.1016/j.ejmech.2014.03.063
DO - 10.1016/j.ejmech.2014.03.063
M3 - Article
SN - 0223-5234
VL - 78
SP - 294
EP - 303
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
ER -